Imbio PHA (4.0.0) vs AVIEW
AI Verdict
Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA if your primary need is rapid, automated assessment of cardiac strain, specifically right ventricular dilation, from CT pulmonary angiogram (CTPA) scans. This tool is ideal for aiding in the diagnosis and risk stratification of acute conditions like pulmonary embolism or for evaluating pulmonary hypertension, providing precise, AI-driven measurements of key cardiac structures for immediate insights.
View Imbio PHA (4.0.0) →Choose AVIEW if…
Choose AVIEW if you require a comprehensive AI platform for the early detection, diagnosis, and long-term monitoring of multiple thoracic conditions from CT scans. This solution is particularly well-suited for programs focused on lung cancer screening, COPD assessment including emphysema quantification, and coronary artery calcification scoring, offering capabilities for longitudinal follow-up and detailed pattern analysis for various lung diseases.
View AVIEW →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Imbio PHA (4.0.0) | AVIEW |
|---|---|---|
| Pricing | Unknown | Subscription; one-off payment |
| Deployment | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). | Cloud-based; Hybrid solution; Locally on dedicated hardware; Locally virtualized (virtual machine, Docker) |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AVIEWAVIEW demonstrates superior usability through its comprehensive workflow automation, including nodule matching for serial CT scans and 3D visualizations, which can significantly enhance a radiologist's efficiency. Clinical validation for AVIEW 2.0 shows radiologists achieving an 89% increase in case throughput and a 60% reduction in interpretation time, indicating a highly optimized user experience.
Clinical Value
AVIEWAVIEW offers broader clinical value by addressing multiple major thoracic diseases, including lung cancer, COPD, and coronary artery calcification, with a wider array of sophisticated AI-powered analyses. It has extensive real-world validation, having processed over 2.5 million cases across 19 countries and being adopted in government-led screening programs. Imbio PHA, while valuable, focuses on a more specific cardiac application.
Pricing & Value
AVIEWAVIEW provides more transparency regarding its pricing model, offering both subscription and one-off payment options based on installations or users. Crucially, AVIEW CAC has secured a US billing code (G0680), indicating formal recognition and potential for reimbursement, which significantly enhances its value proposition for healthcare providers. Imbio PHA only states 'contact for pricing,' offering no immediate insight into its cost structure.
Enterprise Readiness
AVIEWBoth tools offer flexible deployment options (cloud, on-premise, hybrid) and are FDA cleared and HIPAA compliant. However, AVIEW's extensive global adoption in large-scale screening programs across 19 countries and its explicit validation against interoperability standards like IHE and FHIR suggest a higher level of proven scalability and integration capabilities in diverse enterprise environments.
Innovation
AVIEWAVIEW demonstrates greater innovation by providing a comprehensive, integrated AI platform for multiple thoracic diseases, moving beyond task-specific tools to an 'integrated diagnostic ecosystem.' Its advanced features include ILD pattern analysis and the ability to perform coronary artery calcium scoring from standard chest CTs, broadening its clinical utility. Imbio PHA, while innovative in its specific cardiac focus, has a narrower application scope.
Support & Docs
Imbio PHA (4.0.0)Imbio PHA explicitly states it offers 24/7/365 phone and email support to its customers worldwide. It also indicates that user manuals and product documentation are available upon request. While Coreline Soft provides contact information for customer service, the available search results do not offer comparable explicit details regarding 24/7 support availability or the breadth of documentation for AVIEW.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Imbio PHA (4.0.0) | AVIEW |
|---|---|---|
| Product Name | Imbio PHA (4.0.0) | AVIEW |
| Company | Imbio | Coreline Soft Co. |
| Primary Application Area | Cardiac structure measurement from CTPA scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. | Early detection, diagnosis, and monitoring of lung cancer, COPD, and coronary artery calcification from CT scans. |
| Cardiac Measurement Capabilities | Automated measurement of right and left ventricle diameters; Automated measurement of main pulmonary artery and aorta diameters; Calculates RV/LV and PA/Ao ratios. | Coronary artery calcium (CAC) scoring (Agatston, volume, mass score, risk stratification); Automated segmentation of coronary arteries. |
| Lung Analysis Capabilities | Not specified | AI-powered lung nodule detection and characterization (size, volume, type, location, Lung-RADS score); Emphysema quantification and low attenuation area (LAA) analysis; Automated segmentation of lung lobes, airways, vessels; Interstitial Lung Disease (ILD) pattern analysis. |
| Reporting & Integration | Generates annotated DICOM images; Provides summary reports in PDF format; Integrates with native DICOM tools and workflows. | 3D visualizations and comprehensive PDF reports; Workflow automation and integration with PACS/RIS/CIS; Follow-up registration and nodule matching for serial CT scans. |
Videos
Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and AVIEW.